3-((benzyloxy)methyl)-5-bromopyridine | 97000-22-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-((benzyloxy)methyl)-5-bromopyridine
• 英文别名: 3-((Benzyloxy)methyl)-5-bromopyridine；3-bromo-5-(phenylmethoxymethyl)pyridine
• CAS: 97000-22-1
• 化学式: C₁₃H₁₂BrNO
• 分子量: 278.148
• InChiKey: DMYJMSQPNYRTNU-UHFFFAOYSA-N

物化性质

• 沸点：
  354.5±32.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-((benzyloxy)methyl)-5-bromopyridine 在 盐酸 、 potassium permanganate 、 四(三苯基膦)钯 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 5-(3-甲氧基苯基)吡啶-3-甲酸甲酯
  参考文献：
  名称：

  Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of(.+-.)-3-PPP [3-(3-hydroxyphenyl)-1-propylpiperidine]

  摘要：

  In an attempt to enhance the potency of the dopamine autoreceptor agonist 3-PPP, racemic cis-3-(3-hydroxyphenyl)-5-[(methylmercapto)methyl]-N-n-propylpiperidine has been prepared in a stereoselective synthesis. NMR studies of 3 show a diequatorial conformation for the 3- and 5-substituents, which gives compound 3 an intriguing overlap with the ergoline derivative pergolide. Pharmacological testing revealed that 3, which is a 5-(methylmercapto)methyl derivative of racemic 3-PPP does not show the anticipated potency increase as a dopamine autoreceptor agonist. In vitro (inhibition of tyrosine hydroxylation) 3 and 1 have similar potency, and the in vivo potency (inhibition of GBL accelerated dopamine synthesis) of 3 is inferior to that of 1.

  DOI：

  10.1021/jm00147a046
• 作为产物：
  描述：

  氯化烟碱盐酸盐 在 六甲基磷酰三胺 、 sodium tetrahydroborate 、 溴 、 sodium hydride 作用下， 反应 19.0h， 生成 3-((benzyloxy)methyl)-5-bromopyridine
  参考文献：
  名称：

  Synthesis and dopamine autoreceptor activity of a 5-(methylmercapto)methyl-substituted derivative of(.+-.)-3-PPP [3-(3-hydroxyphenyl)-1-propylpiperidine]

  摘要：

  In an attempt to enhance the potency of the dopamine autoreceptor agonist 3-PPP, racemic cis-3-(3-hydroxyphenyl)-5-[(methylmercapto)methyl]-N-n-propylpiperidine has been prepared in a stereoselective synthesis. NMR studies of 3 show a diequatorial conformation for the 3- and 5-substituents, which gives compound 3 an intriguing overlap with the ergoline derivative pergolide. Pharmacological testing revealed that 3, which is a 5-(methylmercapto)methyl derivative of racemic 3-PPP does not show the anticipated potency increase as a dopamine autoreceptor agonist. In vitro (inhibition of tyrosine hydroxylation) 3 and 1 have similar potency, and the in vivo potency (inhibition of GBL accelerated dopamine synthesis) of 3 is inferior to that of 1.

  DOI：

  10.1021/jm00147a046

文献信息

• Palladium-catalyzed difluoromethylation of heteroaryl chlorides, bromides and iodides
  作者：Changhui Lu、Yang Gu、Jiang Wu、Yucheng Gu、Qilong Shen

  DOI：10.1039/c7sc00691h

  日期：——

  A palladium-catalyzed difluoromethylation of a series of heteroaryl chlorides, bromides and iodides under mild conditions is described. A wide range of heteroaryl halides such as pyridyl, pyrimidyl, pyrazyl, funanyl, thienyl, pyazolyl, imidazolyl, thiazolyl, and oxazolyl halides were efficiently difluoromethylated, thus providing medicinal chemists an alternative choice for the preparation of drug

  描述了在温和条件下一系列杂芳基氯化物，溴化物和碘化物的钯催化的二氟甲基化。各种杂芳基卤化物（例如吡啶基，嘧啶基，吡唑基，呋喃基，噻吩基，吡唑基，咪唑基，噻唑基和恶唑基卤化物）被有效地二氟甲基化，因此为药物化学家提供了制备具有二氟甲基化杂芳基单元的候选药物的替代选择。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
  申请人：FUJIFILM Corporation

  公开号：EP2589592B1

  公开（公告）日：2018-08-22
• US8772320B2
  申请人：——

  公开号：US8772320B2

  公开（公告）日：2014-07-08
• US8809371B2
  申请人：——

  公开号：US8809371B2

  公开（公告）日：2014-08-19